补体在人类疾病中的作用:已批准和即将上市的治疗药物
补体系统是抵御血源性病原体和控制免疫与组织稳态的保护者,但补体活性失调与多种炎症和自身免疫性疾病发病相关。尽管临床靶向补体的价值早已被认可,补体药物总体批准率不高;人源化抗C5抗体依库珠单抗在阵发性睡眠性血红蛋白尿和非典型溶血综合征中的成功重新激发了治疗性靶向补体的努力。对补体生物学理解的加深促进了新药物靶点的发现,加上药物发现与开发技术的进步,使将新的补体治疗药物推向临床的兴趣激增。获批药物数量上升但仍几乎仅针对罕见病,而大量在研治疗选择可能为将补体临床靶向扩展至常见病提供机会。
要点
- 补体系统在防御病原体与维持免疫和组织稳态中起保护作用。
- 补体活性失调与多种炎症和自身免疫性疾病的发病或加重相关。
- 人源化抗C5抗体依库珠单抗有效治疗阵发性睡眠性血红蛋白尿和非典型溶血综合征,重新激发了补体治疗药物研发。
核心结论
- 补体活性失调与多种炎症和自身免疫性疾病的发病或加重相关,靶向补体治疗的价值已被认可。
- 已获批补体药物仍几乎仅针对罕见病,但在研治疗选择可能为将补体靶向扩展至常见病提供机会。
研究设计与样本
- 综述,总结已批准和即将上市的补体靶向治疗药物。
主要发现
- 人源化抗C5抗体依库珠单抗有效治疗阵发性睡眠性血红蛋白尿和非典型溶血综合征。
- 对补体生物学理解的加深识别了新的药物开发靶点,药物发现与开发技术的进步使新的补体治疗药物进入临床的兴趣激增。
- 获批补体药物数量上升但仍几乎仅针对罕见病,在研治疗选择 pipeline 规模可观。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The complement system is recognised as a protector against blood-borne pathogens and a controller of immune system and tissue homoeostasis. However, dysregulated complement activity is associated with unwanted or non-resolving immune responses and inflammation, which induce or exacerbate the pathogenesis of a broad range of inflammatory and autoimmune diseases. Although the merit of targeting complement clinically has long been acknowledged, the overall complement drug approval rate has been modest. However, the success of the humanised anti-C5 antibody eculizumab in effectively treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic syndrome has revitalised efforts to target complement therapeutically. Increased understanding of complement biology has led to the identification of novel targets for drug development that, in combination with advances in drug discovery and development technologies, has resulted in a surge of interest in bringing new complement therapeutics into clinical use. The rising number of approved drugs still almost exclusively target rare diseases, but the substantial pipeline of up-and-coming treatment options will possibly provide opportunities to also expand the clinical targeting of complement to common diseases.
引用
- West EE, Woodruff T, Fremeaux-Bacchi V, et al. Complement in human disease: approved and up-and-coming therapeutics. Lancet. 2023. PMID: 37979593. doi:10.1016/S0140-6736(23)01524-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。